(Link) An Op-Ed from Kat McDavitt and Lisa Bari We need a Chief Patient Officer in the US Department of Health and Human Services The Forgotten Man of mRNA Research by the Wall Street Journals (paywall) Gregory Zuckerman If you enjoyed this post, subscribe to Hospitalogy, my newsletter breaking down the finance, strategy, innovation, and M&A of healthcare
Disclaimer: Body Pharm products, including retatrutide, semaglutide and tirzepatide reference materials, are sold for research and analytical purposes only
GLP-1 Receptor Activation: Inhibits appetite, delays gastric emptying, and promotes insulin secretion
It is not a medical instruction nor a recommendation for dosing in humans
After spending $100 million on the drugs for weight loss in 2024 and seeing sizable operating losses to boot, Point32Health announced in May that it would stop automatically covering the drugs for obesity starting in 2026
Trudi, the consultant, has been a friend and very prompt with help and customer service